First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

Kim-Son H Nguyen, Joel W NealStanford Cancer Institute, Stanford University, Stanford, CA, USAAbstract: Epidermal growth factor&ndash;receptor tyrosine kinase inhibitors (EGFR TKIs) were initially established as second- or third-line treatment of advanced non-small-cell lung cancer (NSCLC)....

Full description

Bibliographic Details
Main Authors:	Nguyen KS, Neal JW
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-09-01
Series:	Biologics : Targets & Therapy
Online Access:	http://www.dovepress.com/first-line-treatment-of-egfr-mutant-non-small-cell-lung-cancer-the-rol-a11109

Similar Items

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019-11-01)

Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
by: Gergis, Carol
Published: (2019)

Radiofrequency Ablation with Continued EGFR Tyrosine Kinase Inhibitor Therapy Prolongs Disease Control in EGFR-Mutant Advanced Lung Cancers with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors: Two Case Reports
by: Shi X, et al.
Published: (2020-07-01)

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
by: Yun Jung Choi, et al.
Published: (2013-01-01)

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
by: Keisuke Tabara, et al.
Published: (2012-01-01)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
by: Yun Jung Choi, et al.
Published: (2019-01-01)

Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy
by: Sahrun Sahrun, et al.
Published: (2019-10-01)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
by: Miyoshi S, et al.
Published: (2015-04-01)

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
by: Jeet Gandhi, et al.
Published: (2009-01-01)

Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
by: Yoshinori Tsukumo, et al.
Published: (2020-01-01)

Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
by: Wang S, et al.
Published: (2019-08-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)

Targeting the EPHA2 receptor tyrosine kinase in KRAS and EGFR mutant lung cancer
by: Amato, Katherine Renee
Published: (2015)

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
by: Natalia J. Gurule, et al.
Published: (2021-05-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations
by: Oscar Arrieta, et al.
Published: (2020-09-01)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
by: Eric Santoni-Rugiu, et al.
Published: (2019-07-01)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
by: Nana Zhang, et al.
Published: (2017-01-01)

Resveratrol Decreases the Resistance of Lung Cancer Cells to EGFR Tyrosine Kinase Inhibitor
by: Chu-Ying Peng, et al.
Published: (2010)

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
by: Holleman MS, et al.
Published: (2019-02-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
by: Daniel B Costa, et al.
Published: (2007-10-01)

Association between the detection of EGFR mutations and the efficacy of EGFR-tyrosine kinase inhibitors in lung cancer patients
by: Jeng-Sen Tseng, et al.
Published: (2015)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
by: Sheng-Kai Liang, et al.
Published: (2021-01-01)

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
by: Po-Lan Su, et al.
Published: (2018-09-01)

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
by: Kousuke Watanabe, et al.
Published: (2018-01-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer
by: Po‐Lan Su, et al.
Published: (2021-02-01)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016-10-01)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021-09-01)

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.
by: Yixuan Gong, et al.
Published: (2007-10-01)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
by: Satoshi Takahashi, et al.
Published: (2021-04-01)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
by: Ziyi Xu, et al.
Published: (2021-08-01)

Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients with EGFR-Mutated Non-Small-Cell Lung Cancer
by: Chang CY, et al.
Published: (2021-09-01)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang J, et al.
Published: (2016-06-01)

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer
by: Katherine B. Sahin, et al.
Published: (2021-09-01)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
by: Dong Ha Kim, et al.
Published: (2018-12-01)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
by: Albina Kibirova, et al.
Published: (2019-10-01)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
by: Katsuhiro Yoshimura, MD, et al.
Published: (2017-01-01)